Russell Investments Group Ltd. raised its holdings in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 481.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,787 shares of the specialty pharmaceutical company’s stock after buying an additional 52,818 shares during the quarter. Russell Investments Group Ltd. owned about 0.23% of Paratek Pharmaceuticals worth $1,538,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of PRTK. Renaissance Technologies LLC lifted its holdings in shares of Paratek Pharmaceuticals by 275.9% during the first quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after buying an additional 304,249 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth approximately $3,258,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth approximately $3,258,000. Royce & Associates LP acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth approximately $2,553,000. Finally, Morgan Stanley lifted its holdings in shares of Paratek Pharmaceuticals by 160.2% during the first quarter. Morgan Stanley now owns 154,693 shares of the specialty pharmaceutical company’s stock worth $2,978,000 after buying an additional 95,243 shares during the last quarter. Institutional investors own 82.33% of the company’s stock.

In other news, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the transaction, the vice president now owns 69,500 shares of the company’s stock, valued at approximately $1,638,810. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Evan Loh sold 4,351 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $102,596.58. Following the transaction, the chief operating officer now directly owns 112,783 shares of the company’s stock, valued at approximately $2,659,423.14. The disclosure for this sale can be found here. Insiders have sold a total of 21,960 shares of company stock valued at $524,342 in the last three months. 4.90% of the stock is owned by insiders.

PRTK has been the subject of a number of research analyst reports. BidaskClub lowered Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. HC Wainwright upped their price target on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Saturday, August 5th. Finally, Raymond James Financial, Inc. reiterated a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $37.44.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/paratek-pharmaceuticals-inc-prtk-shares-bought-by-russell-investments-group-ltd/1548737.html.

Shares of Paratek Pharmaceuticals, Inc. (PRTK) traded up 3.13% on Friday, hitting $28.00. The company had a trading volume of 282,194 shares. The company’s market capitalization is $777.31 million. The firm has a 50-day moving average price of $22.19 and a 200 day moving average price of $21.09. Paratek Pharmaceuticals, Inc. has a 12-month low of $9.80 and a 12-month high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.